Erythropoietin News and Research

RSS

Erythropoietin, or its alternative erythropoetin or EPO, is a glycoprotein hormone that controls erythropoiesis, or red blood cell production. It is a cytokine for erythrocyte (red blood cell) precursors in the bone marrow.

Test for blood sugar not accurate in diabetic dialysis patients

The standard test for measuring blood sugar control in people with diabetes is not accurate in those on kidney hemodialysis, according to new research at Wake Forest University Baptist Medical Center.

21 Feb 2008

Standard test for blood sugar control not accurate in diabetic dialysis patients

21 Feb 2008

Anemia treatment may be a double-edged sword

Erythropoietin has so far been known to doctors as a hormone that boosts red-blood-cell production.

4 Feb 2008

New way to boost red blood cell numbers

A common treatment for anemia a deficiency in red blood cells (rbcs) caused by their insufficient production, excessive destruction, or excessive loss is administration of recombinant erythropoietin (Epo), a hormone that stimulates the production of rbc precursors by the bone marrow.

11 Jan 2008

Human hormone shows potential as new antidepressant agent

Novel treatment strategies for major depression with broader treatment success or a more rapid onset of action would have immense impact on public health, a new study published in the December 1st issue of Biological Psychiatry explains.

12 Dec 2007

Study questions impact of hemoglobin variations on mortality in dialysis patients

For patients with dialysis-related anemia, the risk of death is increased when hemoglobin levels remain persistently low over a period several months - not necessarily when they fluctuate over time, according to a study in the January Clinical Journal of the American Society of Nephrology.

5 Dec 2007

New anemia measure predicts risk of death in dialysis patients

A new indicator of variations in hemoglobin level over time is a strong predictor of the risk of death among patients receiving dialysis for end-stage renal disease (ESRD), reports a study in the December Journal of the American Society of Nephrology.

15 Nov 2007

SENP1 protein may provide a basis for future targeted cancer therapies

Researchers at the University of Texas M. D. Anderson Cancer Center have found a protein that enables cellular survival during periods of low oxygen, or hypoxia, which also is key for development of many kinds of cancer.

2 Nov 2007

New discovery on blood doping and anemia

A stunning discovery by German scientists may make blood doping and the treatment of severe anemia as easy as washing your hair.

21 Sep 2007

Scientists tackle gene doping in athletes

Gene doping has the potential to spawn athletes capable of out-running, out-jumping and out-cycling the strongest of champions.

7 Aug 2007

Europe approves MIRCERA to treat anaemia

Roche has announced that the European Commission has approved its innovative drug MIRCERA to treat anaemia associated with chronic kidney disease (CKD).

27 Jul 2007

Key mechanism identified by which the body regulates iron metabolism

Scientists at the University of California, San Diego (UCSD) have determined a key mechanism by which the body regulates iron metabolism, a discovery that may provide new approaches for the treatment of anemia.

23 Jun 2007

FDA Panel warns anemia drug dangerous for cancer patients

A panel of experts advising the Food and Drug Administration (FDA) in the United States has warned that the popular anemia drug erythropoietin may not be as safe as first thought.

14 May 2007

Caution against over-aggressive use of erythropoiesis-stimulating agents for cancer-related anemia

Echoing recent FDA warnings, a research group from Northern Ireland cautions against over-aggressive use of a group of drugs called "erythropoiesis-stimulating agents" (ESAs) to treat anemia in some cancer patients, according to a commentary in the April issue of The Oncologist, published by AlphaMed Press.

1 May 2007

Anti-anemia drug darbepoetin alfa no better than placebo for cancer patients

Results from a phase III drug trial indicate that an anti-anemia drug did not significantly decrease the need for blood transfusions in patients not on chemotherapy, and decreased overall patient survival when compared to placebo, according to researchers from the UCLA Medical Center at the 2007 Annual Meeting of the American Association for Cancer Research.

17 Apr 2007

FDA strengthens safety information for Erythropoiesis-Stimulating Agents (ESAs)

The U.S. Food and Drug Administration (FDA) has issued a public health advisory outlining new safety information, including revised product labeling about erythropoiesis-stimulating agents (ESAs), widely-used drugs for the treatment of anemia.

11 Mar 2007

Darbepoietin alpha may provide cardiac protection 24 hours after heart attack

A drug has been shown to provide some protection to the heart from injury even if given as much as 24 hours after a heart attack, Jefferson Medical College researchers report.

28 Nov 2005

Novel human kidney protein called renalase that regulates both heart contraction and blood pressure

Researchers at Yale School of Medicine and the VA Connecticut Healthcare System in West Haven identified a novel human kidney protein called renalase that regulates both heart contraction and blood pressure; it is a strong candidate for easily administered treatment of advanced kidney and cardiovascular disease.

10 Apr 2005

NIH awards grant to explore causal relationship between epoetin dose and survival of hemodialysis patients

The National Institutes of Health, National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) has awarded a two-year grant to the Medical Technology and Practice Patterns Institute (MTPPI) in collaboration with Harvard School of Public Health (HSPH) to explore the causal relationship between epoetin dose and survival of hemodialysis patients receiving this therapy.

27 Feb 2005

Researchers have identified a protein called HIF-2a, which is important in retina formation

Hoping to prevent blindness in premature babies, UT Southwestern Medical Center researchers have identified a protein that responds to oxygen levels in cells and tissues and also affects the developing eye.

22 Feb 2005